Prevents pregnancy. ANDA 206864, held by Naari Pte. Ethinyl Estradiol; Norethindrone.
As of Nov 16, 2026, ANDA 206864 (Norethindrone And Ethinyl Estradiol), held by Naari Pte, was first approved by FDA on Apr 28, 2017, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Norethindrone and ethinyl estradiol tablets, USP 1 mg/0.035 mg are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the NORPLANT System depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 28, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norethindrone And Ethinyl Estradiol0.035MG;1MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone | Rx |
| Apr 29, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 28, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters